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Abstract The impact of headache disorders is a problem of
enormous proportions, both for individual and society. The
medical literature tried to assess its effects on individuals, by
examining prevalence, distribution, attack frequency and
duration, and headache-related disability, as well as effects
on society, looking at the socio-economic burden of head-
ache disorders [Rasmussen (Cephalalgia 19:20–23, 1999)];
[Lanteri-Minet et al. (Pain 102:143–149, 2003)]. The issue of
costs represents an important problem too, concerning both
direct and indirect costs. Direct costs concern mainly
expenses for drugs. Migraine has a considerable impact on
functional capacity, resulting in disrupted work and social
activities: many migraineurs do not seek medical attention
because they have not been accurately diagnosed by a phy-
sician or do not use prescribed medication [Solomon and
Price (Pharmacoeconomics 11:1–10, 1997)]. Indirect costs
associated with reduced productivity represent a substantial
proportion of the total cost of migraine as well. Migraine has
a major impact on the working sector of the population, and
therefore, determining the indirect costs outweighs the direct
costs. This study will explain the notion of cost of illness,
examining how it could be applied in such a framework.
Then, an overview of the studies aimed at measuring direct
and indirect costs of migraine and headache disorders will be
carried out, later shifting on to the relationship between costs
and quality of life for people affected by headache disorders.
Finally, a brief review on advantages of new pharmaceuticals
and preventive treatments for migraine for patients and
society will outline improvements in the context of cost-
effectiveness and cost-utility analysis.
Keywords Migraine  Cost of illness  Disease costing 
Economic evaluation
Introduction
Migraine is a very common disorder, affecting about 11%
of adult populations in Western countries. Migraine can be
classified among cephalalgias, a kind of disease widespread
in the population: the percentages of the adult population
with active headache disorders are, globally, 46% for
headache in general, 11% for migraine, 42% for tension-
type headache and 3% for chronic daily headache [25].
Prevalence of migraine is highest during the peak pro-
ductive years—between 25 and 55 years of age.
The prevalence is higher in females than males at all
post-pubertal ages, but the sex ratio varies with age [16].
On the World Health Organization’s ranking of causes of
disability, headache disorders are among the ten most
disabling conditions for the two genders, and among the
five most disabling conditions for women.
Hence, the impact of headache disorders is a problem of
enormous proportions, both for individual and society. The
medical literature tried to assess the effects on individuals,
by examining prevalence, distribution, attack frequency
and duration, and headache-related disability, as well as its
effects on society, looking at the socio-economic burden of
headache disorders [14, 22].
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The issue of costs represents an important problem too,
concerning both direct and indirect cost. Direct costs
concern mainly expenses for drugs.
Drugs are not often considered in an appropriate way:
most of the people suffering from migraine, in fact, manage
their headaches without conventional medical advice and
generally treat their attacks with over-the-counter medi-
cation. This often gives rise to a high percentage of visits to
different health professionals and, once the disease has
become chronic, to a large number of prescriptions for
medication, which in turn produces an increase in costs
[27].
Migraine has a considerable impact on functional
capacity, resulting in disrupted work and social activities:
many migraineurs do not seek medical attention because
they have not been accurately diagnosed by a physician or
do not use prescribed medication [23]. Indirect costs
associated with reduced productivity represent a substantial
proportion of the total cost of migraine as well. Migraine
has a major impact on the working sector of the population,
and therefore, determining that indirect costs outweigh the
direct costs.
It has been estimated that chronic headache is one of the
most costly illnesses of modern society, on account of its
widespread presence in industrialised countries [14].
During the last years, several studies on chronic head-
aches have further analysed the costs, stressing the negative
influence of headache on quality-of-life parameters [4],
including their influence on functioning ability or work
ability.
Treatment with new drugs represents a new emerging
therapeutic tool in the field of headache treatment, with
promising application for chronic forms. Together with the
appearance of new pharmaceuticals, the creation of spec-
ialised headache centres has to be mentioned, and the
dissemination of programmes to educate general practi-
tioners and other health care specialists in matters
concerning headache, that where implemented, have led to
positive results [27].
Since standardised measures to evaluate losses of utility
due to migraine have not been properly developed so far,
the issue of costs is still the most relevant: the approach of
cost of illness is particularly well suited to analyse the
burden of headache: moreover, it allows to correctly
evaluate the extent of benefits (i.e. reduction of costs) that
is possible to obtain from a preventive cure of migraine.
This study is organised as follows. The next section will
explain the notion of cost of illness, examining how it
could be applied in such a framework. Then, an overview
of the studies aimed at measuring direct and indirect costs
of migraine and headache disorders will be carried out,
later shifting on to the relationship between costs and
quality of life for people affected by headache disorders.
Finally, a brief review on advantages of new pharma-
ceuticals and preventive treatments for migraine for
patients and society will outline improvements in the
context of cost-effectiveness and cost-utility analysis.
Cost of illness and headache
‘‘Cost of illness’’ represents economic evaluation method-
ology through which it is possible to determine the cost
caused by illnesses on the population.
The principal aim of the economic evaluation method is
to define explicit value of the human life and thereby, to
determine the cost in terms of loss of productivity caused
by death of an individual.
More recently, this approach has been used to calculate
the social and economic costs, in terms of loss of produc-
tivity, caused by a disease that only in the most serious
cases results in the death of an individual.
The production losses resulting from morbidity are
reflected in work-time reductions that may be calculated
through absence. Recent studies have demonstrated that, in
EU countries, the loss of productivity caused by headache
represents one of the most important problems.
The production losses, also defined as indirect costs, are
not the only social costs caused by diseases. Drummond [7]
pointed also to the negative variations that are reflected on
the two fundamental quantities: consumption of resources
and state of health.
The former is also defined as direct costs. Patients in
primary care with headache cost at least 87% more than
their similar-age and same gender counterparts without
headache [8]. Patients with migraine exact as much as
1.6-fold higher overall costs in comparison to patients
without migraine [5]. Direct costs include all the health-
care costs caused by a disease, from its diagnosis to the
patient’s treatment and rehabilitation. Hence, this means
the clinical and instrumental analyses called for by a
diagnosis, the drugs, as well as any other therapeutical
measure (i.e. surgical operation, radiotherapy). The
resources include the services provided by the health
personnel (physicians, nurses and other workers) and that
part of overhead costs imputable to the disease. Hospital
costs universally represent only a very small portion of
total migraine management costs [13].
These are the most easily identifiable costs. However, it
is still not possible to precisely quantify the direct costs of
migraine because there is general agreement that a high
percentage of migraneurs never consult a physician for their
illness—between 19% and 44% in the various studies—and
only a small percentage (from 16% to 36%) regularly
consult their physician. They may be differentiated
depending on who provides the resources: the healthcare
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service or else the patients and their relatives. Such a dis-
tinction proves useful as it permits to detect the differences
existing between disease costing—this being an economic
appraisal method—and the financial analyses that only
consider those costs that affect the year-end figures of a
business. Indeed, economic appraisal is a method for eval-
uating social costs, regardless of whoever bears them.
The calculation of direct costs must also include a
number of costs that are not related to healthcare, such as
the time needed to get to the facilities providing healthcare
services. They also include transportation costs, and wait-
ing-time costs, provided that this time is not subtracted
from the productive activity since, otherwise, this would
lead to duplication where it would be also calculated
among production losses. In the case of a few pathologies
one must also include special diets, changes in the home in
the case of a few home-delivered treatments, or in one’s
clothes, when a prosthesis or a different medical device is
called for.
So, there are more problems connected to the cost of
illness related to headache. It still appears as a method that
can lead to different results in accordance with the utilized
principle of evaluation.
We need to consider not only the social dimension of
illness (headache), but the real possibility to reduce costs,
thanks to existing technologies (medical devices, drugs
etc…) too.
Direct and indirect costs of migraine
The financial burden of migraine has constituted the main
issue of many analyses. Goldberg [11] has seen how
migraine determines costs totaling as much as 17 billion
dollars in the United States. Most of the costs are for
outpatient services, such as medications, office or clinic
visits, emergency department visits, laboratory and diag-
nostic services, and management of treatment side effects.
Of the total annual cost associated with treatment of
migraine, about one tenth ($1.5 billion) goes to medication,
with triptans accounting for the majority of this amount
($1.18 billion).
Triptans are selective 5-HT receptor agonists that are
specific and effective treatments in the management of
migraine: they meet the acute treatment goal of rapid relief
with minimal side effects. Triptans are also associated with
improved quality of life [6].
These agents are highly effective, but with a mean cost
per prescription of $160, they are also among the leading
contributors to cost. When properly used, their clinical
effectiveness justifies their cost. However, their cost is not
definitive: regarding their use, the triptans are not inter-
changeable, and costs as well as clinical outcomes may
vary with different agents in this class and according to
patients’ response.
Indirect costs, whose estimate is of more of 14.5 billion
dollars (of which 7.9 billion dollars was due to absentee-
ism, 5.4 billion dollars to diminished productivity, and 1.2
billion dollars to medical costs), add substantially to the
total [13, 24].
Emphasis on indirect costs can be seen in the study by
Lipton et al. [17]: given that severe migraine can lead to
disruption of work, family and social life, the direct costs
of migraine, due to medical care, are small compared with
the indirect costs caused by absence from work and
reduced productivity.
The authors stress how population-based studies are
required to assess incidence, prevalence and distribution of
the disease. Studies already existing in literature, in fact,
reveal that migraine is currently underdiagnosed and un-
dertreated. Measures of severity may be useful as
predictors of disability and healthcare use: moreover, such
measures may also be useful in assessing the need for
patient care and treatment and help target those more dis-
abled by migraine. As a conclusion, the identification of
patients who need more care and their treatment should
reduce the impact of migraine on the individual and the
burden of migraine on society.
In another study, Lipton et al. [18] stress once again the
enormous health burden on individual and on society
imposed by headache (the authors mention both headache
and migraine). The condition affects about 18% of women
and about 6% of men across their lifespan. Because its
prevalence peaks during the most productive years,
migraine is an important cause of lost work time. The focus
of this study is just on work losses that are not uniformly
distributed: the most disabled half of migraineurs account,
in fact, for more than 80% of all work loss.
Hu et al. [13] attempt a comprehensive estimate of the
financial burden of migraine in the US, considering mainly
indirect costs. The authors look at several indicators:
• Bedridden days per year. Migraine-related disability
was calculated as a function of the number of bedridden
days in patients aged between 20 and 64 years based on
results of a previous study (the Baltimore County
Migraine Study). Subjects reported how often they
needed bed rest when experiencing a migraine attack;
response options were: never, rarely, less than 50% of
the time, and more than 50% of the time; for
calculations, these were translated into rates of 0, 10,
25, and 75%. An average percentage of attacks in
which patients need bed rest (PAB) was generated for
each age and sex stratum. Total number of bedridden
days per year (BDY) in the given age and sex stratum
was calculated as follows:
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BDY ¼ NMS  FAY  PAB  ABH=24
where NMS is the number of migraine sufferers in an age
and sex stratum, FAY the frequency of migraine attacks per
year, ABH the average bedridden hours when lying down
with a migraine attack. By dividing by 24, bedridden hours
were converted into bedridden days.
• Health care resource use. The costs of health care
resource utilisation associated with migraine were
obtained from an analysis of 1994 data from MED-
STAT’s MarketScan data set. This included both
inpatient, outpatient, and prescription drug claims for
employees and their dependents for more than 40 large
employers in the United States. For outpatient encoun-
ters, either primary or secondary diagnoses were
accepted. For hospitalizations, only the principal diag-
nosis was accepted. Migraine-related drug costs were
estimated only for those patients who had at least one
migraine-related medical encounter.
• Economic loss due to missed workdays. Missed work-
days and impaired work performance were combined
with data from the Bureau of Labor Statistics with
respect to percentage of population working for pay and
average working hours per week.
The total number of migraine-related missed workdays
(TMWD) per year was calculated for each age- and sex-
specific stratum as follows:
TMWD ¼ NMS  MWD  PWP  WHW=40
where MWD is average migraine-related missed workdays
per year, PWP is the percentage of the population working
for pay, estimated at 73% for males and 57% for females,
WHW is the average working hours per week, most
recently reported as 35 working hours for both sexes.
Divided by 40, working hours have been converted into
the standard fulltime level (8 working hours per day).
Impaired work performance was calculated as a function
of the number of workdays with migraine (NWDM) and
reduced work efficiency during the attacks. The NWDM
was estimated as follows:
NWDM ¼ NMS  WDM  PWP  WHW=40:
The average number of workdays with migraine (WDM)
per year was estimated based on patient self-report.
Lost workday equivalent (LWDE) due to impaired work
performance was calculated as follows:
LWDE ¼ NWDM  1  EWMð Þ;
where EWM is the average effectiveness at work with
migraine, estimated at 42% for men and 34% for women.
• Economic loss due to reduced productivity. The total
employment lost due to migraine (TELM) in dollar
terms was calculated as follows, assuming 8 h for each
working day:
TELM ¼ TMWD þ LWDEð Þ  hourly salary  8:
The analysis put in evidence what extent patients with
migraine are frequently disabled during their acute attacks.
Although migraine-related disability can be reflected by both
bedridden days and restricted activities, the authors
emphasized bedridden days because they can be more
reliably reported and quantified. About one-third of migraine
sufferers experienced severe disability or the need for bed
rest following attacks, and an additional 50% reported mild
or moderate disability. However, the overall estimates still
do not capture several important components of the burden
of disease. There is room for further analyses that should be
carried out bearing in mind that direct costs represent a small
proportion of the overall societal costs of migraine (therefore
analyses should concentrate on indirect costs).
Nevertheless, there are a few reasons to believe that
even the direct costs have been underestimated. This con-
clusion derives by considering that medical claims do not
capture all migraine-related treatment costs because the
disease is often not treated with specific therapies. More-
over, it is quite complicated to measure over-the-counter or
preventive medications and nondrug-related interventions.
Indirect costs are the main content of a recent study by
Hawkins et al. [12]: to estimate the indirect burden of ill-
ness of migraine, the authors compared the average annual
indirect expenditures of a group of employees with
migraine with a matched group of employees without
migraine (control group). The burden of illness of migraine
was defined as the difference in average indirect expendi-
tures per person between migraine and control cohorts.
Indirect cost components included in this study were
workplace absence, short-term disability and workers’
compensation claims.
Controls were matched to the migraine cohort according
to the predicted probability of having a migraine; this
probability was estimated for each patient on the basis of a
logistic regression analysis of having a migraine that con-
trolled for demographics (age, gender, region, location,
year, and type of insurance) and overall comorbidities.
A second-stage regression was used to estimate the
indirect burden of migraine. Specifically, the second-stage
regression used total indirect expenditures as the dependent
variable and the same independent variables used in the
propensity score matching, plus a dummy indicator to
denote migraine patients. The second-stage regression
estimated by applying a generalized linear model (GLM),
controlled for any remaining differences between the
cohorts after matching.
It was estimated that employees with migraine cost
employers approximately $12 billion per year due to
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absenteeism, short-term disability, and/or workers’ com-
pensation claims. Most of the indirect migraine
expenditures were driven by absenteeism. Results of the
study confirm that the overall burden of migraine on
society is large.
In a cross-study comparison, the estimated per-
employee absenteeism plus short term disability expendi-
tures for migraine in this study were shown to be greater
than those of other common conditions such as chronic
obstructive pulmonary disorder, heart disease, depression,
chronic renal failure, diabetes, and asthma.
Compared with the study by Hu et al., which found
absenteeism costs to be about $8 billion ($10.1 billion 2004
dollars), the estimate of absence cost from the current study
($9 billion), which used a different methodological
approach was consistent although total indirect burden of
illness estimated by Hawkins et al. cannot be directly
compared with the estimate from Hu et al., as the two
studies captured different sets of indirect cost components:
specifically, Hu et al. did not include short-term disability
and workers’ claims.
These results are very important when viewed in terms
of the loss of production capacity (debility) that occurs
when a sick individual goes to work—presenteeism: an
individual suffering from migraine will not show the same
level of productivity as a non-suffering individual.
Some authors have shown how presenteeism was the
most important driver of overall costs, and how its impact
was greatest in patients with migraine/headache, account-
ing for 89% of the total cost burden [10].
The authors conclude their study mentioning the thera-
peutic opportunities for headache and potential advantages:
higher direct costs, due to more expensive drugs, could be
offset by savings in indirect costs (i.e. reduced and lost
productivity).
Other international studies have estimated the burden of
migraine: Bigal et al. [3] have conducted such an analysis
for Brazil, implementing both a cost-analysis and a cost-
effectiveness analysis. The objective of their study is to
address national health expenses in the most efficient way.
Data refer to 1999 and distinguish among Brazilian
demographic characteristics, characteristics of the public
health system related to primary, secondary, and tertiary
care, the last being subdivided into emergency department
and hospital care, and estimation of the number of migraine
consultations at each complexity level.
The authors stress how in Brazil, migraineurs seen in the
public health system most often are discharged with an
acute treatment, usually a non-specific medication: this
way of intervention is compared with a proposed stratified
care model that uses triptan as an acute care medication.
The annual costs of the treatment were calculated
according to the following equation:
AC ¼ P  N  C þ P  Cp þ P  Cat  AMA;
where P is the number of patients, N is the number of
consultations per patient, C is the cost of consultation per
level, Cp is the cost of preventive drugs, Cat is the cost of
acute therapy drugs, AMA is the number of migraine
attacks per year, and produced the following results: the
estimated cost of a consultation for migraine on the pri-
mary care level was US $11.53; on the secondary care
level, US $22.18; in the emergency department, $34.82;
and for hospitalization, US $217.93. Hence, the total esti-
mated public health system expenses for migraine were US
$140 388 469.60. The model proposed by authors that
include specific acute migraine therapies, would imply a
cost reduction of 6.2% (US $7 514 604.40), improving, at
the same time, the level of quality of care of the public
health system.
Recently, Vinding et al. [26] have estimated the burden
of headache in a patient population from a specialized
headache centre in Denmark. The sample was made of 55
patients (12 males and 43 females) whose median headache
frequency was of 15 days/month; information was col-
lected through structured interviews, prospective headache
diaries and standardized self-administered questionnaires.
The interview contained a total of 116 questions about the
socio-economic impact of headache disorders. The inter-
view included an extensive description of the influence on
working ability, personal impact, utilization of health ser-
vices and medicine, and was conducted by a trained
medical student blinded to the remaining information about
headache diagnosis, frequency and medication use.
Very high utilization of the healthcare system and a high
absence rate due to headache of 12 days/year were repor-
ted. Eighty-one percent of patients experienced a marked
decrease in work effectiveness. Overall, 91% felt hampered
by their headache on a daily basis and 98% had had
expenses for headache medication. The absence rate
reported by the study was highly skewed as 19% (nine
patients) were[60 days absent from work due to headache
and of those, 10% (n = 5) had been absent a full year. Due
to headache, 90% (43/48) had been absent from work at
least once and due to all causes 96% (47/49) had had at
least one absent day during the last year.
Further specification could be added to analyses when
estimating the burden of headache according to different
levels of pain. Auray [2] takes the classification made by
the International Headache Society that distinguishes three
categories for headache. The author carried out an exten-
sive survey on a sample of 10 585 individuals in the French
adult population (data of 1999). The results showed a
prevalence of 17.3% for migraine and nearly 30% for
headaches. The average expenditure for a headache patient
is about 220 Euro (10% for GP consultations, 11% for
J Headache Pain (2008) 9:199–206 203
123
laboratory evaluations, 17% for specialist consultations,
18% for drugs and 44% for hospital costs). However, this
partition of cost depends largely on the headache category:
in the same way, it could be concluded that, although the
most acute headaches lead to the most severe deterioration
of quality of life, professional or school activities are not
affected similarly.
Overall, it could be concluded that costs, both direct and
indirect, are unknown: it is now established that the indi-
rect costs of migraine outweigh the direct costs and
therefore represent an obvious target for healthcare inter-
vention, aimed at reducing the impact of migraine [23]:
these conclusions come from a study carried out in 1997,
but they could be well replicated today.
Migraine and quality of life
A different approach followed by more recent studies is
based on quality of life rather than economic evaluation.
Despite the prevalence and substantial economic burden
of migraine, no standardized measures of quality of care
exist.
Gagne et al. [9], in a study aimed at drawing a com-
prehensive review for quality of care measures, stress how
no standardized measures for measuring quality of life for
patients suffering from migraine have been developed so
far. For example, the Health Plan Employer Data and
Information Set, maintained by the National Committee for
Quality Assurance is widely used in the US to assess
quality of care at the health-plan level, but it does not
include any headache, or migraine-related measures. This
may be due, in part, to a lack of understanding of migraine
or its underdiagnosis. For example, migraine was not even
included in the first Global Burden of Disease in 1990 [15].
The American Migraine Prevalence and Prevention Study
found that only 56.2% of those with migraine had ever
received a medical diagnosis.
Since many publications provide insights into the large
clinical and economic burden of the disorder, patients,
employers, disease management providers, and health
plans alike would benefit from a standardized set of
migraine quality measures.
A review about the existing quality of care measures for
migraine is carried out by Gagne et al. [9]: such measures
include patient-reported measures and non-patient repor-
ted, diagnosis-related, prevention-related, and treatment-
related indicators.
Most existing measures have been developed by the
Institute for Clinical Systems Improvement or summarized
and reported by the RAND Corporation. However, few
migraine care quality measures exist, and those that are
available are not easily implemented at the health-plan
level. Hence, significant effort is still needed to determine
what and how to measure quality among health plans to
improve the quality of care delivered to individuals with
migraine.
Leonardi et al. [15] summarize classification for dis-
ability due to headache according to WHO classification:
using disability-adjusted life years as a summary measure
of population health (which adds disability to mortality),
WHO has shown that mental and neurological disorders
collectively account for 30.8% of all years of healthy life
lost to disability whilst migraine; one amongst these, alone
accounts for 1.4% and is among the top 20 causes of dis-
ability worldwide. This information is combined with the
increasing widely accepted belief that disability and func-
tioning are relevant parameters for monitoring the health of
nations and that there is an increasing need to measure
them.
Classification of functioning, disability and health
applied to headache disorders allows comparability with
other health conditions as well as evaluation of the role of
the environment as a cause of disability amongst people
with headache.
Treatment of migraine with new drugs
and improvements in terms of cost savings
and quality of life
Appropriate treatment of migraine can, of course, decrease
the level of costs [6]. Given the level of costs, likely to
interest such a high percentage of population affected by
migraine, prevention, early intervention or effective treat-
ment strategies for headache disorders may be highly cost
effective.
Cost-effective models can be used to understand the
effect of treatment choices on health care budgets. All
aspects of effectiveness (efficacy, tolerability, and cost)
should be considered to reduce overall managed care
expenditures for migraine treatment.
The choice of a new or an old therapeutic treatment
depends on a number of factors. Moreover, the evaluation
of the cost, in terms of economics, but also in terms of
quality of life and type of facilities necessary for one
treatment are crucial criteria. Treatment with new drugs
represents a new emerging therapeutic tool in the field of
headache treatment, with promising application for chronic
forms.
In evaluating treatment strategies not only the activity of
a drug in reaching the main end-points, (i.e. pain free or
headache relief) should be considered, but also the safety
and perception of safety by patients, and the cost effec-
tiveness, including indirect costs compared with personal
and social benefits. There is no evidence of cost-benefit
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analysis as suggested by Pini et al. [21]. Rather, there are
several cost-effectiveness studies aimed at evaluating cost-
effectiveness ratios for triptans or other drugs [4, 28].
Migraine prophylaxis is aimed at preventing frequent
attacks and the development of a long-term condition that
often incurs heavy costs for abortive treatment, diagnostic
services, and medical care. Agents approved for migraine
prophylaxis include the antiepileptics divalproex and to-
piramate and the beta blockers propranolol and timolol. As
with abortive therapy, costs vary widely among these
prophylactic agents.
A new approach to migraine prophylaxis is injection of
botulinum toxin [19]. Overall, positive results have been
reported concerning the reduction of the duration and the
intensity of the attacks, as well as the muscle contraction.
Prophylactic migraine treatment effectiveness has been
evaluated by many studies: it is possible to mention, for
example, the article by Adelman and Von Seggern [1] to
see how issues concerning advantages of preventive treat-
ment had already been considered more than a decade ago.
An individual approach is, however, required: Pierangeli
et al. [20] warn about the need to weigh the potential
benefits against the adverse effects associated with each
agent in determining the optimal preventive regimen for
individual patients considering any co-morbid condition.
Moreover, an important role has to be played by the
physician as regarding the decision to treat and the choice
of prophylactic drug that should be taken with the patient.
What is important is to balance expectations and thera-
peutic realities for each drug.
Conclusion
By way of conclusion, it should be recalled that in the
headache field we are far behind other pathologies, where
there is a greater knowledge of the economic aspects of
both the pathology-related costs and the likely benefits
resulting from different therapeutical approaches.
It may be noted that there are still many unsolved
problems in disease costing, to the point that it still appears
as a set of method that may lead to extremely different
outcomes depending on the evaluation approach being used.
In any event, it should be noted that, in this context, one
needs to take into account not only the social cost of a
given disease, but also the real possibilities of cutting down
those costs thanks to the existing technologies, meaning the
diagnostic, therapeutic and rehabilitative tools that are
already available or are being adopted.
Notwithstanding the disease costing problems, which
are also reflected in the cost-benefit approaches, it is
important for the economic analysis to gain ground since
there is a growing need to keep account of the available
resources and the results attainable in the healthcare poli-
cies, from the central to the peripheral levels, where the
above-referred evaluation tools referred prove even more
expedient.
Moreover, given the social relevance of migraine, it
should be important to increase the knowledge related to
the economic consequences of prevention through an
increase of availability of health service.
From the analysis of prevalence, incidence, morbidity
and consequence of the state of health caused by headache,
it seems important to awaken the scientific community and
policy makers to the problems connected to the economic
costs of headache and how it should be faced using the
implementation of specified ‘‘observatory.’’
For that reason it is essential to increase economic
evaluation studies to be able to estimate economic and
financial costs of headache (i.e. see The Global Campaign
to Reduce the Burden of Headache Worldwide—WHO).
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